Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SCPS Stock Summary
In the News

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster's pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr. Laster to cause all shares of Scopus common stock held by him to be present in person or by proxy at the Annual Meeting and any adjournments thereof exclusively for the purposes of establishing a quorum at the meeting, Dr. Laster failed to satisfy this requirement by both not attending the Annual Meeting in person and not making his shares present by proxy.

Scopus BioPharma to Present at the LD Micro Main Event
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.

Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice

Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pursuant to a stipulation with Morris C. Laster, M.D. in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the company's scheduled October 8, 2021 Annual Meeting of Stockholders (the “Annual Meeting”) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties. The company and Dr. Laster intend to conduct discussions in an effort to seek to resolve the disputes between the parties and have also agreed to an expedited timeline for resolving the Delaware court action.

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors
SCPS Financial details
SCPS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.05 | -0.18 | -0.87 | -1.52 | -0.55 | |
Operating cash flow per share | -0.05 | -0.14 | -0.19 | -0.66 | -0.39 | |
Free cash flow per share | -0.05 | -0.14 | -0.19 | -0.66 | -0.39 | |
Cash per share | 0 | 0 | 0.14 | 0.46 | 0.01 | |
Book value per share | 0 | -0.01 | -0.14 | 0.23 | -0.31 | |
Tangible book value per share | 0 | -0.01 | -0.14 | 0.23 | -0.33 | |
Share holders equity per share | 0 | -0.01 | -0.14 | 0.23 | -0.31 | |
Interest debt per share | 0 | 0 | 0.22 | 0.04 | 0 | |
Market cap | 88.66M | 88.66M | 198.31M | 28.21M | 2.06M | |
Enterprise value | 88.65M | 88.62M | 198.76M | 20.26M | 1.93M | |
P/E ratio | -129.24 | -32.96 | -17.14 | -1.07 | -0.18 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -118.63 | -41.81 | -78.53 | -2.47 | -0.25 | |
PFCF ratio | -118.63 | -41.73 | -78.53 | -2.47 | -0.25 | |
P/B Ratio | -16.65K | -1.07K | -108.29 | 7.02 | -0.31 | |
PTB ratio | -16.65K | -1.07K | -108.29 | 7.02 | -0.31 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -129.24 | -32.95 | -19.57 | -0.73 | -0.16 | |
EV to operating cash flow | -118.63 | -41.79 | -78.71 | -1.77 | -0.24 | |
EV to free cash flow | -118.63 | -41.71 | -78.71 | -1.77 | -0.24 | |
Earnings yield | -0.01 | -0.03 | -0.06 | -0.93 | -5.64 | |
Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.41 | -3.95 | |
Debt to equity | -25.9 | -10.31 | -2.08 | 1.04 | -1.14 | |
Debt to assets | 1.04 | 1.11 | 1.93 | 0.51 | 19 | |
Net debt to EBITDA | 0 | 0.01 | -0.04 | 0.29 | 0.01 | |
Current ratio | 0.96 | 0.9 | 0.52 | 1.96 | 0.05 | |
Interest coverage | 0 | 0 | -14.38 | -35.67 | 0 | |
Income quality | 1.09 | 0.79 | 0.23 | 0.42 | 0.69 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -6.4 | 0 | -1.33 | -0.9 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.02 | 0.15 | 1.63 | 2.82 | 1.96 | |
ROIC | -5.3 | -3.85 | 6.4 | 3.5 | -81.12 | |
Return on tangible assets | -5.17 | -3.49 | -5.86 | -3.21 | -29.6 | |
Graham Net | -0.01 | -0.05 | -0.15 | 0.22 | -0.35 | |
Working capital | -5.33K | -86.52K | -1.83M | 4.01M | -7.06M | |
Tangible asset value | -5.33K | -82.86K | -1.83M | 4.02M | -7.06M | |
Net current asset value | -5.33K | -86.52K | -1.83M | 4.01M | -7.06M | |
Invested capital | 0 | 0 | -1.25 | 0 | 0 | |
Average receivables | 41.26K | 14.21K | 281 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 128.8 | 32.46 | 6.32 | -6.54 | 1.77 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.22 | -0.16 | -0.09 | -0.08 | -0.08 | |
Operating cash flow per share | -0.19 | -0.14 | -0.04 | -0.02 | -0.03 | |
Free cash flow per share | -0.19 | -0.14 | -0.04 | -0.09 | -0.03 | |
Cash per share | 0.19 | 0.05 | 0.01 | 0.01 | 0.05 | |
Book value per share | -0.03 | -0.18 | -0.26 | -0.31 | -0.23 | |
Tangible book value per share | -0.03 | -0.18 | -0.26 | -0.33 | -0.25 | |
Share holders equity per share | -0.03 | -0.18 | -0.26 | -0.31 | -0.23 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 14.58M | 9.07M | 5.11M | 2.06M | 1.84M | |
Enterprise value | 10.6M | 7.91M | 4.8M | 1.93M | 443.48K | |
P/E ratio | -0.78 | -0.68 | -0.67 | -0.3 | -0.19 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.67 | -3.15 | -6 | -4.87 | -2.43 | |
PFCF ratio | -3.66 | -3.15 | -6 | -1.04 | -2.43 | |
P/B Ratio | -27.48 | -2.45 | -0.93 | -0.31 | -0.27 | |
PTB ratio | -27.48 | -2.45 | -0.93 | -0.31 | -0.27 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.28 | -2.38 | -2.53 | -1.05 | -0.17 | |
EV to operating cash flow | -2.67 | -2.75 | -5.63 | -4.58 | -0.58 | |
EV to free cash flow | -2.66 | -2.75 | -5.63 | -0.98 | -0.58 | |
Earnings yield | -0.32 | -0.37 | -0.37 | -0.84 | -1.33 | |
Free cash flow yield | -0.27 | -0.32 | -0.17 | -0.96 | -0.41 | |
Debt to equity | -9.69 | -1.45 | -1.08 | -1.14 | -1.34 | |
Debt to assets | 1.12 | 3.21 | 14.24 | 19 | 5.81 | |
Net debt to EBITDA | 0.85 | 0.35 | 0.16 | 0.07 | 0.52 | |
Current ratio | 0.9 | 0.31 | 0.07 | 0.05 | 0.17 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.85 | 0.87 | 0.45 | 0.23 | 0.28 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 3.67 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -2.55 | 0 | 0 | -6.71K | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.35 | 0.79 | 0.73 | 0.76 | 0.64 | |
ROIC | 1.39 | 0.55 | 9.22 | -12.09 | 2.04 | |
Return on tangible assets | -1.01 | -1.98 | -4.57 | -4.41 | -1.53 | |
Graham Net | -0.06 | -0.2 | -0.27 | -0.35 | -0.26 | |
Working capital | -533.84K | -3.7M | -5.51M | -7.06M | -7.71M | |
Tangible asset value | -530.43K | -3.7M | -5.5M | -7.06M | -7.71M | |
Net current asset value | -533.84K | -3.7M | -5.51M | -7.06M | -7.71M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 2.69M | 2.69M | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 8.79 | 0.9 | 0.34 | 0.26 | 0.35 | |
Capex per share | 0 | 0 | 0 | -0.07 | 0 |
SCPS Frequently Asked Questions
What is Scopus BioPharma Inc. stock symbol ?
Scopus BioPharma Inc. is a US stock , located in New york of Ny and trading under the symbol SCPS
What is Scopus BioPharma Inc. stock quote today ?
Scopus BioPharma Inc. stock price is $0.051 today.
Is Scopus BioPharma Inc. stock public?
Yes, Scopus BioPharma Inc. is a publicly traded company.